COHBAR INC COM USD0.001 (OTCMKTS:CWBR) has seen a nice run since Friday of last week. CWBR’s bullish run comes after a second quarter where the company generated a wider than expected net loss of (-$1.9) million compared to a net loss of (-$1.5) million reported in Q2 2016.
CWBR rocketed up 31.4% after the company said it will present promising preclinical results for its lead candidate drugs CB4209 and CB4211. CWBR is set to make a presentation at The Liver Meeting 2017 slated for October 20-24, 2017 in Washington D.C.
COHBAR INC COM USD0.001 (OTCMKTS:CWBR) lead preclinical development program is based on MOTS-c, a mitochondrial-derived peptide discovered in 2012 by the Company’s founders and their academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company has developed novel, improved analogs of the MOTS-c peptide, CB4209 and CB4211, which have demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity.
CWBR is an innovative biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CWBR’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CWBR’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including NASH, obesity, type 2 diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.
Find out when $CWBR reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
CWBR, still at the preclinical stage, is investigating CB4209 and CB4211 for the treatment of nonalcoholic Steatohepatitis (NASH) and obesity. Early this year, the company reported strong results as it continued to advance the two drug candidates through IND-enabling activities. Plans are already underway to initiate human clinical trials early next year.
“The Liver Meeting is the most prominent gathering of scientists and clinicians in the field of hematology, and we are pleased to have the opportunity to present the promising preclinical results from our CB4209 and CB4211 lead candidates,” commented Kenneth C. Cundy, Ph.D. – Chief Scientific Officer of CohBar.
CWBR also expanded its pharmaceutical partnering activities by teaming up with Torreya Partners. The two have already met up with major Pharma companies in the NASH space as part of an effort that seeks to explore ways of advancing the development of the companies lead candidate drugs.
COHBAR INC COM USD0.001 (OTCMKTS:CWBR) has a market cap of $256.21M and 39.30M shares outstanding. CWBR could be at an inflection point, but, if you know anything about biotechs, you know that they are unpredictable and can be rather pesky when it comes to forecasting their future trajectory. However, CWBR has battled through some tough news recently and has strong tech in their back pocket. So, watch how this one takes shape and how the clinical trials come out. Sign-up for continuing coverage on shares of $CWBR stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $CWBR, either long or short, and we have not been compensated for this article.